PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media280218ArticlesСтатьиResearch Article“Slozhnaya” bronkhial'naya astma - sovremennoe sostoyanie problemy“Сложная” бронхиальная астма - современное состояние проблемыBiteevaD. VБитееваД. ВGoryachkinaL. AГорячкинаЛ. А

к.м.н., профессор

DrobikO. SДробикО. С

к.м.н.

KonishchevaA. YuКонищеваА. Ю

к.м.н.

РМАПО, Москва10112013201sNO1s (2013)№1s (2013)404825022023Copyright ©; 2013, Bionika MediaCopyright ©; 2013, ООО «Бионика Медиа»2013Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/280218

“Complicated" bronchial asthma (BA) is a serious medical and social problem associated with high morbidity and mortality, and amounts of up to 80 % of all health care costs for the treatment of BA. Understanding the immunological and pathogenic features of the disease led to the identification of different BA phenotypes and confirmed the need for expanding the choice of available therapeutic approaches. The results of the study involving 25 patients with uncontrolled severe atopic asthma showed that combination therapy (inhaled corticosteroids/ long-acting β2-agonists + montelukast 10 mg) for 24 weeks significantly optimizes clinical and functional control of the disease, and partly improves control of airway inflammation.

“Сложная" бронхиальная астма (БА) является серьезной медико-социальной проблемой, связанной с высоким уровнем заболеваемости и летальности, составляет до 80 % всех затрат здравоохранения, предназначенных для лечения БА. Понимание иммунологических и патогенетических особенностей заболевания привело к выделению различных фенотипов БА и подтвердило необходимость расширения выбора доступных терапевтических подходов. Результаты проведенного исследования с участием 25 пациентов с неконтролируемым тяжелым течением атопической БА показали, что комбинированная терапия (ингаляционные кортикостероиды/длительно действующие β2-агонисты + монтелукаст 10 мг) в течение 24 недель позволяет значительно оптимизировать клинико-функциональный контроль заболевания, а также отчасти улучшать контроль воспаления дыхательных путей.

control of bronchial asthmaphenotypespharmacotherapyконтроль бронхиальной астмыфенотипыфармакотерапияBeasley R. The Global Burden of Asthma Report, Global Initiative for Asthma (GINA). Available from http://www.ginasthma.org.Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59(5):469-78.Demoly P,Gueron B, Annunziata K, et al. Update on asthma control in five European countries: results of a 2008 survey. Eur Respir Rev 2010;19(116):150-57.Garcha-Marcos L, Quirys AB, Hernondez CG, et al. Stabilization of asthma prevalence among adolescents and increase among schoolchildren (ISAAC phases I and III) in Spain. Allergy 2004;45:1301-307.Reddel HK, Taylor DR, Bateman ED, et al. An Official American Thoracic Society/European Respiratory Society Statement: Asthma control and Exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59-99.Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008;32:545-54.Экспертный совет по здравоохранению Комитета совета Федерации по социальной политике и здравоохранению. Социальноэкономическое бремя астмы и хронической обструктивной болезни легких в Российской Федерации. М., 2010. 15 с.Asthma in America. www.asthmainamerica. com.Rabe KF, Vermeire PA, Soriano JB, et al. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000;16:802-7.Gene RJ, Antuni JD, Sano F, et al. Asthmacontrolin Latinamerica and Caribbean countries: correlation between asthma control test (ACT), FEV1 and current treatment ERS. In: European Respiratory Sosiety Conference 2009 abstract. 2009. Poster 3050.Chapman KR. Sub-optimal asthma control: prevalence, detection and consequences in primary practice. Eur Respir J 2008;31:320-25.Partridge MR, van der Molen T, Myrseth SE, et al. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006;6:13.Walters R, et al. EAACI Congress 2009;(Abstract)167.Bateman E, Reddel HK, Ericson G, et al. Overall asthma control: The relationship between current control and future risk. J Allergy Clin Immunol 2010;125(3):600-8.Bousquet J, et al. GINA guidelines on asthma and beyond. Allergy 2007;62:102-12.Kwok MY, et al. Pediatr 2006;117:71-7.Здравоохранение в России. Стат. Сборник. Росстат. М., 2009. 365 с.Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006;368:780-93.Morjaria J, Polosa R. Recommendation for optimal management of severe refractory asthma. J Asthma Allergy 2010;3:43-56.Expert panel Report 3 (EPR-3): Guidelines for the diagnosis and management of Asthma-Summary Report 2007. J Allergy Clin Immunol 2007;120:94-138.Hastie AT, Moore WC, Meyers DA, et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 2010;1028-36.The ENFUMOSA Study Group. The ENFUMOSA crossectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003;22:407-77.Wensel S. Asthma: defining of the persistent adult phenotypes. Lancet 2006;368:804-13.Severe Asthma Working Group of the SEAIC Asthma Committee. Consensus Document on the Diagnosis of Severe Uncontrolled Asthma. Esmon PublicidadJ Investig Allergol Clin Immunol 2012;22(7):460-75.King CS, Moores LK. Clinical asthma syndromes and important asthma mimics. Respiratory Care 2008;53;5:568-80.Lynch JP III, Kazerooni EA, Gay SE. Pulmonary sarcoidosis. Clin Chest Med 1997;18:755-85.Ober C. Perspectives on the past decade of asthma genetics. J Allergy Clin Immunol 2005;116(2):274-78.Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2006;117(3):522-43.Kemp JP, Cook DA, Incaudo GA, et al. Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. Salmeterol Quality of Life Study Group. J Allergy Clin Immunol 1998;101:188-95.Chung KF. The complementary role of glucocorticosteroids and long-acting beta-adrenergic agonists. Allergy 1998;53(Suppl. 42):7-13.Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid: Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219-24.Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-88.Holgate ST, Davies ST. Rethinking the pathogenesis of asthma. Immunity 2009;31:362-67.Busse W. The role and contribution of leukotrienes in asthma. Ann Allerg. Asthma Immunol 1998,81(1):17-26.Chanes P, Bougeard Y, Vachier I, et al. Leukotriene antagonists. A new therapeutic approach in asthma. Presse Med 1997;26(5):234-39.Chung К, Holgate S. Leukotrienes: why are they important mediators in asthma? Eur Respir Rev 1997;7(46):259-63.Wenzel SE. The role of leukotrienes in asthma. Prostaglandins Leukot Essent Fatty Acids 2003;69:145-55.Reiss Т, Chervinsky P, Dockhorn R, et al. Montelukast, a once-daily leukotriene receptor antagonists in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998;158(11): 1213-20.Noonan MJ, Chervinsky P, Brandon M, et al. Montelukast: a potent leukotriene recep tor antagonist, causes dose-related improvements in chronic asthma. Eur Respir J 1998;11: 1232-39.Löfdahl CG, Reiss TF, Leff JA, et al. A leukotriene receptor antagonist, montelukast, allows tapering of inhaled corticosteriods while maintaining asthma control: a randomized, placebo controlled trial. BMJ 1999;319:1-4.Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. Br Med J 2003;327:891-97.